Fig. 3From: Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort studyBest percentage change in target lesion size from baseline. Note: The upper dashed line at + 20% represents the threshold for progressive disease. The lower dashed line at -30% represents the boundary for partial response. * New lesion appeared in this patientBack to article page